Comparison

KRIBIOLISA™ Rat Anti-Ranibizumab (Lucentis) ELISA

Item no. KRIS-KBI2029r
Manufacturer Krishgen Biosystems
Amount 1 x 96 wells
Category
Type Elisa-Kit
Applications ELISA
Specific against Rat (Rattus norvegicus)
Sensitivity 76 ng/ml
Dry ice Yes
ECLASS 10.1 32160605
ECLASS 11.0 32160605
UNSPSC 41116126
Shipping condition Dry ice
Available
Manufacturers Category
Krishgen- Biopharma-PK-ADA; Biosimilars / Biotherapeutics; Immunogenecity Assays
HSN Code
38220090
Short Description
Enzyme Immunoassay for the quantitative determination of Anti-Ranibizumab in serum and plasma
Manufacturers Sample Type
Serum and Plasma
Description
Introduction:
Ranibizumab (Lucentis) is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and
inhibits vascular endothelial growth factor A (VEGF-A). VEGF is a biochemical signal protein that promotes
angiogenesis throughout the body and in the eye. Through binding to VEGF-A, ranibizumab interrupts the
interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels.
Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been
subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has
been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology,
pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing)
autoantibodies against Ranibizumab and can be responsible for allergic reaction, or even anaphylactic shock.
This ELISA kit detects antibodies for Anti-Ranibizumab and may be used for monitoring immunogenicity.

Intended Use:
The KRIBIOLISA™ Rat Anti-Ranibizumab ELISA is used as an analytical tool for quantitative determination of
Anti-Ranibizumab in rat serum.

Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Ranibizumab is pre-coated
onto microwells. Samples and standards are pipetted into microwells and antibodies to Ranibizumab present in
the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Ranibizumab
is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use
substrate solution (TMB) is added to microwells and color develops proportionally to the amount of AntiRanibizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is
measured at 450 nm. 
Shipping Temp
2 - 8 degrees C

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 x 96 wells
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close